Breast cancer patients with high expression of aldehyde dehydrogenases (ALDHs) cell population have higher tolerability to chemotherapy since the cells posses a characteristic of breast cancer stem cells (BCSCs) that are resistant to conventional chemotherapy. In this study, we found that the ALDH-positive cells were higher in CD44 + CD24 − and CD44 + CD24 − ESA + BCSCs than that in both BT549 and MDA-MB-231 cell lines but microRNA-7 (miR-7) level was lower in CD44 + CD24 − and CD44 + CD24 − ESA + BCSCs than that in MDA-MB-231 cells. Moreover, miR-7 overexpression in MDA-MB-231 cells decreased ALDH1A3 activity by miR-7 directly binding to the 3′-untranslated region of ALDH1A3; while the ALDH1A3 expression was downregulated in MDA-MB-231 cells, the expressions of CD44 and Epithelium Specific Antigen (ESA) were reduced along with decreasing the BCSC subpopulation. Significantly, enforced expression of miR-7 in CD44 + CD24 − ESA + BCSC markedly inhibited the BCSC-driven xenograft growth in mice by decreasing an expression of ALDH1A3. Collectively, the findings demonstrate the miR-7 inhibits breast cancer growth via suppressing ALDH1A3 activity concomitant with decreasing BCSC subpopulation. This approach may be considered for an investigation on clinical treatment of breast cancers.
2007; Zhou et al., 2009) . Therefore, targeting eradication of BCSCs or reducing the BCSC subpopulation is a crucial strategy to achieve effective treatment of breast cancer.
A high activity of aldehyde dehydrogenases (ALDHs) defends intracellular homeostasis by catalyzing the conversion of toxic aldehydes into nontoxic carboxylic acids; whereas ALDH-positive breast cancer cells are closely correlated with higher metastasis and recurrence rates and poor clinical outcome in patients. The cells have been shown to be a biological marker of CSCs in many cancers including breast cancer (Charafe-Jauffret et al., 2010; Lugli et al., 2010; Sterzyńska et al., 2018; Zhou et al., 2018) . There is growing body of evidence showing the CD44 + CD24 − CD44 + CD24ESA + (also called CD326 or EpCAM, epithelial cell adhesion molecule), and ALDHs in breast cancer cells are well-accepted molecular markers of BCSCs Zhang et al., 2014) . ALDHs activity is widely used in the identification of BCSCs, which is usually measured with the ALDEFLUOR test and flow cytometry (FCM) analysis .
Emerging research has indicated that microRNA-7 (miR-7) is a breast cancer suppressor that inhibited the multiple oncogenes such as SET domain bifurcated 1, epidermal growth factor receptor (EGFR), and Kruppel-like factor-4 (KLF-4), etc., in the breast cancer cell lines (Huynh & Jones, 2014; Jeong et al., 2017) . Although we have previously found that the overexpression of miR-7 reduced the BCSC subpopulation and partially reversed epithelial-mesenchymal transition (EMT) in human breast cancer MDA-MB-231 cell line , however, the molecular mechanisms have remained unclear. Since the BCSC subpopulation generally affects breast cancerʼs chemoresistance, progression, metastasis, and recurrence Polonio-Alcalá et al., 2018) , a better understanding of the mechanisms of decreasing BCSC subpopulation regulated by miR-7 might shed insight into new therapeutic strategy for treatment of breast cancers.
In this study, we extend the previous study and investigate the mechanisms of miR-7 reducing the BCSC subpopulation in vitro and in vivo mouse model. Our data showed that miR-7 directly reduced ALDH1A3 (ALDH1 family member A3) positive cells and decreased the CD44 + CD24 − ESA + BCSC subpopulation in MDA-MB-231 cells.
Furthermore, enforced expression of miR-7 suppressed the ALD-H1A3 activity and the BCSCs-driven xenograft growth in nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice. The study provides an evidence that therapeutic application of cancer inhibitor miR-7 may be a novel therapeutic method for treatment of breast cancer.
| MATERIALS AND METHODS

| Ethical statement
This study was performed with approval of the Animal Care and Use Committee of School of Medicine, Southeast University, China. Full details of approval of the study can be found in the approval ID:
20080925. Human breast cancer BT549, MDA-MB-231, and SK-BR-3 cell lines   were obtained from the Cellular Institute in Shanghai, China. BT549 and SK-BR-3 cells were maintained in 1640 medium (Gbico).
| Cell lines
MDA-MB-231 cells were cultured in Dulbeccoʼs Modified Eagleʼs
Medium. All medium consist of 2 mM L-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin, and 10% fetal bovine serum.
| Flow cytometry
To detect the purity of BCSCs and ALDH1 activity, the CD44, CD24, ESA antibodies (eBioscience), and the ALDH1 enzyme assay kit (Invitrogen, Carlsbad, CA) were applied on a FCM (BD Biosciences) according to the manufacturerʼs instructions and as described previously (Dave et al., 2014; Hosea, Hardiany, Ohneda, & Wanandi, 2018) .
| Reverse transcription quantitative real-time polymerase chain reaction
To test the expression of miR-7, CD44, KLF4, ALDH1A3, and ESA, reverse transcription quantitative real-time polymerase chain reaction (RT-qPCR) analyses were used and performed on an ABI step one plus real-time system (Applied Biosystems). Total cellular RNA was isolated from each sample by using a Qiagen RNeasy kit (Qiagen, Valencia, CA).
The messenger RNA (mRNA) levels of the genes of interest were expressed as the ratio of each gene of interest to glyceraldehyde 3phosphate dehydrogenase mRNA per sample. The complementary DNAs (cDNAs) were amplified by RT-qPCR with primers were listed in Table 1 . (Cruz-Lozano et al., 2018; Wang et al., 2015) .
| Dual-luciferase reporter assay
We used the miRcode algorithm (release 6.2, http://www.mircode. org/) to search for miR-RNA target of ALDH1A3. The wild/mutated ALDH1A3 were developed by PCR from human genomic DNA. For luciferase reporter assay, PmirGLO dual-luciferase miRNA target expression vector (psiCHECK2-ALDH1A3-3′-untranslated region (3′-UTR; psiCHECK2-ALDH1A3-3′-UTR-Mut) were used in MDA-MB-231 and SK-BR-3 cells Zhang et al., 2014) .
Luciferase reporter assay was performed using the Dual-Luciferase
Reporter Assay System (Promega). The luciferase activity was measured 48 hr posttransfection (Chiyomaru et al., 2013) .
| Western blotting
Approximately 1 × 10 6 MDA-MB-231, Lenti-miR-7-MDA-MB-231, Lentivector-MDA-MB-231 cells, or tumor tissue homogenate were collected and lysed in the protein extraction buffer (Novagen, Madison, WI) by following the manufacturerʼs protocol. 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis was performed and proteins (10 μg/lane) were transferred onto a polyvinylidene difluoride membrane blocked with 4% dry milk in Tris-buffered saline with Tween-20 for 1 hr at 22°C, and then incubated respectively with either the rabbit antibody specific to human ESA or ALDH1A3 (Proteintech, Chicago), KLF4 (Santa Cruz Biotechnology, CA), and CD44 (Proteintech), respectively overnight at 4°C. The antibody dilution was 1:1,000. Immunoreactive bands were detected by Odyssey scanning instrument (LI-COR Odyssey Imaging System; Dou et al., 2012; Wang et al., 2015) . Nagle et al., 2018) .
| Magnetic activated cell sorting for preparation of BCSCs
CD44, CD24, and ESA antibodies conjugated to magnetic microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany) were used to obtain the BCSCs from the BT549 and MDA-MB-231 cell lines. The sorting method following the manufacturerʼs instructions and our previous studies. We named CD44 + CD24 − cells or ESA + CD44 + CD24 − cells for BCSCs (Dou et al., 2007; Yang et al., 2014; Zhang et al., 2014) . After having identified the ALDH1A3 activity, we used the ESA + CD44 + CD24 − BCSCs to perform the succedent experiments in vitro and in vivo.
| Lentivirus encoding miR-7 infection
To obtain the enforced expression of the miR-7 cells, lentivirus encoding miR-7 or blank vector was infected into MDA-MB-231 as previously described (J. S. Zhang et al., 2014) . The clones with the stable miR-7 expression were selected by GFP expression, and then used in infection of ESA + CD44 + CD24 − BCSCs.
| Cell cycle
A total of 1 × 10 6 ESA + CD44 + CD24 − BCSCs infected with Lenti-miR-7 recombinant, the Lentivector recombinant, and without infection, were respectively fixed overnight with 70% (w/vol) ice-cold ethanol.
Cells were then resuspended in 1 ml of phosphate-buffered saline (PBS) containing 40 μg/mL Annexin-V/propidium iodide (PI) and 500 U/ml RNase A. Following incubation for 30 min in the dark at room temperature, cells were analyzed by FCM using the ModFit software system. The PI fluorescence signal peak versus the integral was used to discriminate G2-M cells from G0-G1 doublets. Cell cycle detection kit was procured from KeyGen Biotech of China (Asharani, Low, Kah Mun, Hande, & Valiyaveettil, 2009 ).
| Animal experiment
The healthy female-specific pathogen-free NOD/SCID mice (age 6-7 weeks) and weighing 17-18 g were purchased from the Beijing Weitong Lihua Experimental Animal Technology Co., Ltd., China, and raised in individual ventilated cages at 22-25°C in Experimental Animal Center, School of Medicine, Southeast University. Each NOD/ SCID mouse received inoculation of 2 × 10 5 Lenti-miR-7-BCSCs or BCSCs or Lenti-vec-BCSCs at mouseʼs right inguinal mammary fat pads, 12 mice were divided to three groups of equal size (four per T A B L E 1 Primer sequences used for RT-qPCR
Gene
Sequence (5′-3′)
Abbreviations: ALDH, aldehyde dehydrogenase; ESA, epithelium specific antigen; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; KLF, Kruppel-like factor; MiR, microRNA; RT-qPCR, reverse transcription quantitative real-time polymerase chain reaction. group). About 32 days after the injection, the developed tumors were tangible. Tumor formations in the groups were monitored every 3 days by 2-dimensional measurements of individual tumors from each mouse. The mice were also monitored for the tumor-free mice, survival mice, and general health indicators, such as feeding, appearance of fur, and so forth. All tumors were harvested 53 days after implantation. The tumor tissues were applied for the western blotting, RT-qPCR, and immunohistochemistry (IHC ) assays. All the experiments were repeated twice .
| IHC and image analysis
The methodology used to detect the molecules of Ki67, CylinD1, ALDH1A3, CD44, and ESA by IHC assay. Briefly, 5-μm-thin formalin fixed and paraffin-embedded slides were incubated with the rabbit antimouse/human antibodies specific for Ki67, CylinD1, ALDH1A3, CD44, and ESA overnight at 4°C. The negative control was generated by replacing the primary antibody with PBS. The samples were then labeled with horseradish peroxidas-conjugated streptavidin (Invitrogen) and the chromogenic reaction that was developed using Liquid 
| Statistical analysis
Values of interest were presented as the mean plus or minus standard deviation. Statistical comparisons were performed using Studentʼs t test method. p < .05 was considered statistically significant.
3 | RESULTS
| Expressions of ALDH and miR-7 in breast cancer cells
To identify ALDH1A3 expression, we first analyzed the ALDH1A3 activity by FCM in BT549 and MDA-MB-231 cell lines. The results
showed that there were more counts of ALDH positive cells in CD44 + CD24 − and CD44 + CD24 − ESA + BCSCs than both BT549 and MDA-MB-231 cells (Figure 1a ,b) which are significant difference between the CD44 + CD24 − BCSCs and BT549 cells (Figure 1e ; p < .0019) or between the CD44 + CD24 − ESA + BCSC and MDA-MB-231 cells or CD44 + CD24 − BCSCs (p < .0007 or .006; Figure 1f ). We found the ALDH positive cells was more obvious in MDA-MB-231 cells (2.64%) and MDA-MB-231 CD44 + CD24 − BCSCs (19.17%) than in BT549 cells (1.01%) and BT549 CD44 + CD24 − BCSCs (2.13%).
Although both MDA-MB-231 and BT549 cell lines are the estrogen receptor (ER − ), progesterone receptor (PR − ), EGFR2 (HER2 − ), a triple-negative breast cancer cell lines , the BT549 cells may be a weaker malignant cancer cells than MDA-MB-231 cells that contain more ALDH-positive cells.
Interestingly, the ALDH1A3 activity was significantly decreased in MDA-MB-231 cells transiently transfected with miR-7 mimic, or siALDH1A3 but not in the miR-7 mimic control, miR-7 inhibitor control, and miR-7 inhibitor (Figure 1c ), or ALDH1A3 negative control (siNC) cells (Figure 1d ), which were statistically significant as is shown in Figure   1g . In contrast, the miR-7 expression was a lower in CD44 + CD24 − and CD44 + CD24 − ESA + BCSCs than that in MDA-MB-231 cells, which was statistically significant (p < .0013 or .0009) as is shown in Figure 1h .
3.2 | miR-7 inhibits the stem-like molecular expression in MDA-MB-231 cells
To confirm the reducing cancer stem-like molecule ALDH1A3 expression mediated directly by miR-7, we next performed luciferase reporter assays. By TargetScan and miRcode algorithm prediction, we found that (Figure 5b) , the one out of 4 mice injected with Lenti-miR-7 BCSCs developed the visible tumors, however, the measurable tumor was not detected in remaining three mice in the 53-day observation period. (Figures 5a,b ). There were a statistically significant differences in tumor sizes between the BCSC-Lenti-miR-7 and BCSC-Lentivector groups, and between the BCSC-Lenti-miR-7 and BCSC groups (Figure 5b) . Figure 5c BCSC-Lentivector or BCSCs, which was statistically significant (Figure 5d ).
Further, we evaluated these molecular expression by RT-qPCR and western blot assays. In accordance with the IHC results, the transcription expressions of ALDH1A3, CD44, and ESA were significantly reduced in the BCSCs infected with Lenti-miR-7 compared with the control cells (Figure 5e ). The results were further supported by the results from the western blot (Figure 5f ). The sample, from the tumor tissues in the mice injected by BCSC-Lenti-miR-7, indicated weaker bands of ALDH1A3, CD44, and ESA than those in the sample from the BCSC-Lentivector or BCSCs, which were statistically significant as is shown in Figure 5G .
| DISCUSSION
Since the CSCs are a subpopulation of cancer cells that are tightly associated with the chemoresistance and recurrence among cancer patients (Bak et al., 2018; Bledzka et al., 2017; Boo et al., 2016; Das & Law, 2018; Liu et al., 2018) , we focused on the BCSCs in the present study and investigated the mechanisms of miR-7 reducing BCSC subpopulation.
Owing to the breast cancer cells with expression of ALDHs exhibiting stem cell-like features (Choi et al., 2018; Matsunaga et al., 2018; Okuda et al., 2013) , we first adopted the ALDEFLUOR assay, a widely used method in detecting the activity of ALDH enzyme in various cancer types, to analyze the ALDH expression in breast cancer cell lines. As expected, the CD44 + CD24 − and CD44 + CD24 − E-SA + BCSCs revealed factually the higher ALDH activity than both BT549 and MDA-MB-231 cells, accompanied with a low miR-7 expression, especially in CD44 + CD24 − ESA + BCSCs. Given the different enzyme isoforms within the ALDH family having differential function, it was report that knockdown of ALDH1A3 in breast cancer cells decreased ALDH activity but did not alter proliferation, extravasation, or therapy resistance; while knockdown of ALDH1A1 reduced breast cancer cell metastatic behavior and therapy resistance (Croker et al., 2017; Marcato et al., 2011) . Therefore, we selected ALDH isozyme, ALDH1A3 to evaluate the influence on breast cancer cell behaviors in the present study. Meanwhile, we enforced the miR-7 expression by using Lenti-miR-7 transduction to address the functional significance of the miR-7 in MDA-MB-231 cells. Our results indicated that the overexpression of miR-7 not only decreased ALDH1A3 expression but also reduced the expressions of the BCSC-related molecules CD44 and KLF-4 in MDA-MB-231 cells. Luciferase reporter assay results demonstrated that the putative miR-7 directly bond the 3′-UTR of ALDH1A3 vector resulting in inhibition of ALDH1A3 expression, which was further supported by western blot analysis ( Figure 2) . The results suggested that reduction of ALDH1A3 activity was associated with inhibition of BCSC stem-like molecule expression.
It was reported that ALDH1A3-induced differential etinoic acid signaling in breast cancer cells and the number of ALDH1A3-positive cells, a marker for breast cancer-initiating cells, which affected the rate of breast cancer progression (Bhat et al., 2019; Marcato et al., 2015) . To this end, we downregulated ALDH1A3 expression by using RNA interference in MDA-MB-231 cells to evaluate the influence of ALDH1A3 on the expression of BCSC stem-like molecules. We found that the knockdown of ALDH1A3 reduced the CD44 and ESA expressions in MDA-MB-231 cells and decreased the BCSC subpopulation (Figure 3 ), suggesting the function of ALDH1A3 is closely related to CD44 + ESA + BCSC subpopulation.
Based on these observations, we whereafter transduced the Lenti-miR-7 recombinant into CD44 + CD24 − ESA + BCSCs to assess the influence of enforced miR-7 expression on BCSC-driven xenograft growth in NOD/SCID mice. The in vivo results indicated the mice injected with Lenti-miR-7-BCSCs initially developed tumor xenograft 10 days after injection. Surprisedly, the established tangible tumor xenografts in three mice were gradually shrunk and eventually vanished, only one tumor in mice kept very smaller tumor size than that in mice injected with Lenti-vector BCSCs or BCSCs. This suggested that miR-7 as anticancer reagent indeed inhibited breast cancer growth in mouse model.
In addition, consistent with the results of tumor tissue sections analyzed by immunohistochemistry, western blot analysis showed the molecular expressions of ALDH1A3, CD44, and ESA were significantly reduced in tumor tissues in the mice injected with
Lenti-miR-7-BCSCs compared with the tumor tissues in the mice injected with Lenti-vector-BCSCs or BCSCs. On the basis of these findings, we conjectured that enforced miR-7 expression in BCSCs attenuated the BCSCʼs stem-like properties, reduced the ALDH1A3 activity, and decreased the BCSCs tumorigenicity, which revealed the miR-7 expression and ALDH1A3 levels has the close connection in breast cancer progression.
Our findings resembled a recent report by Matsunaga et al., where they proposed that ALDH activity is associated with the malignancy of cancer cells and is used for identification and isolation of BCSCs. Administration of ALDH inhibitor N,N-diethylaminobenzaldehyde increased the antitumor and antimetastatic effects in 4T1 cell-implanted mice (Choi et al., 2018; Matsunaga et al., 2018) ,which supported that the inhibition ALDH function suppressed implanted breast cancer in mouse model. In our current study, the decrease of ALDH1A3 expression led to reducing the BCSC subpopulation, which inhibited an implanted BCSC growth in mice. However, a few questions remain unanswered. For example, we do not know the inhibition of ALDH1A3 activity is how to affect the expressions of CD44 and ESA in MDA-MB-231 cells, which leads to the decrease of the BCSC subpopulation, and future study warrants to understand the mechanisms of the reducing BCSC subpopulation mediated by miR-7 overexpression.
In summary, our data represent the first attempt to demonstrate miR-7 attenuates the BCSCs characteristics and reduces the BCSC subset by decrease of ALDH1A3 activity, which inhibits BCSC-driven xenograft growth in mice. The findings suggest the ALDH1A3 is a potentially therapeutic target for treatment of breast cancer.
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